Introduction: Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized cardiomyopathy in majority cases presented as restrictive cardiomyopathy. The diagnosis is often delayed mostly because of the false assumption that it is a rare disease. Emerging noninvasive imaging modality such as Tc99m scintigraphy can provide accurate screening for ATTR. We hypothesized that AATR can be seen in heart failure (HF) patients irrespective of features considered as pathognomonic for cardiac amyloidosis.
Aim: To evaluate prevalence of cardiac ATTR by Tc99m pyrophosphate (PYP) scintigraphy in patients with HF with reduced (HFrEF, LVEF <40%) and middle range ejection fraction (HFmrEF, LVEF 40-49%).
Methods: Thirty-four (mean age 66.8±13 years, 62% males) patients with HF and LVEF<50% without CAD referred to our Heart Failure clinic where included in this study (23 with HFrEF, 11 with HFmrEF) and underwent echocardiography and planar and SPECT Tc99m -PYP.
Results: Out of 34 patients 19 patients had NYHA FC I-II and 15 patients NYHA FC III. The mean LVEF was 35±7.7%, mean interventricular septum was 11±2.3 mm, mean posterior wall 9.9±2.3 mm. There were 6 (18%) patients with mildly positive Tc99m-PYP scan, 11 (32%) patients with strongly positive Tc99m-PYP scan and 17 (50%) patients with negative Tc99m-PYP scan. No significant difference was observed in the prevalence of positive Tc99m-PYP scan between patients with HFmrEF and patients with HFrEF. No statistically significant difference between positive vs. negative scans regarding LVEF and LV end-diastolic diameter was found.
Conclusion: In this pilot study ATTR for the first time has been described in half of the patients with non-ischemic cardiomyopathy. In contrast to a widely accepted notion that cardiac amyloidosis is generally considered to be a condition of preserved EF, normal sized and hypertrophic LV, we found a sizeable proportion of positive Tc99m-PYP scan among patients with LV dysfunction without typical features of ATTR.